INTRODUCTION: Treatment with 5-alpha reductase inhibitors (5ARI) is commonly utilized for the treatment of benign prostatic hyperplasia (BPH).
The true prevalence of sexual side effects with 5ARI treatment is currently unknown.
AREAS COVERED: The current article reviews the reported adverse effects of 5ARI in regard to erectile function, sexual desire and ejaculation. A PubMed search was performed of all articles from 1990 to present, which reported any sexual side effects with finasteride or dutasteride. Preference was given to more recent and human studies where available.
EXPERT OPINION: Clinical trials with 5ARI report prevalence rates of de novo erectile dysfunction of 5 - 9%. Decreased circulating dihydrotestosterone (DHT) resulting from 5ARI use is associated with diminished sexual desire and/or orgasm. The presence of adverse sexual effects is associated with decreased self-esteem, quality of life and ability to maintain an intimate relationship. Inhibition of 5ARI additionally influences progesterone and deoxycorticosterone levels and may alter psychological functions, including increased depression, melancholy and loss of general well being. Ejaculatory dysfunction has not been well studied in patients using 5ARI. Patients receiving therapy with 5ARI should be counseled as to potential sexual and psychological adverse effects. Future clinical studies are needed to further investigate the sexual side effects associated with this class of drugs.
Written by:
Gur S, Kadowitz PJ, Hellstrom WJ. Are you the author?
Tulane University Health Sciences Center, Departments of Urology and Pharmacology, New Orleans, LA 70112, USA.
Reference: Expert Opin Drug Saf. 2013 Jan;12(1):81-90.
doi: 10.1517/14740338.2013.742885
PubMed Abstract
PMID: 23173718
UroToday.com Erectile Dysfunction Section
